Kalaris Therapeutics, Inc.KLRS
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · kalaristx.com
Kalaris Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases. Founded by scientist Dr. Napoleone Ferrara, whose pioneering research led to the development of anti-VEGF therapy, the company is developing TH103, a dual-action anti-VEGF therapeutic, in a Phase 1b/2 study for neovascular Age-related Macular Degeneration.
Key ratios
ROA
-31.0%TTM
2025
-45.1%2024
-681.0%2023
-232.7%
ROE
-79.9%TTM
2025
-308.1%
Recent news
Track KLRS in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer